Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective signal study of Imetelstat in patients with refractory anemia with ring sideroblasts with (RARS-T) or without (RARS) thrombocytosis

Next Previous
Trial Profile

Prospective signal study of Imetelstat in patients with refractory anemia with ring sideroblasts with (RARS-T) or without (RARS) thrombocytosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Sideroblastic anaemia
  • Focus Adverse reactions; Pharmacogenomic

Most Recent Events

  • 25 Feb 2016 According to a Geron Corporation media release, results for safety and efficacy from this study were presented at the 57th American Society of Hematology annual meeting.
  • 10 Nov 2015 According to a Geron Corporation media release, results from this study will be presented at the 57th American Society of Hematology annual meeting
  • 09 Nov 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top